Stage IV CD30+ anaplastic large cell lymphoma: Response to acitretin and interferon‐α
Identifieur interne : 002182 ( Main/Exploration ); précédent : 002181; suivant : 002183Stage IV CD30+ anaplastic large cell lymphoma: Response to acitretin and interferon‐α
Auteurs : Colin Ong [Australie] ; John Sullivan [Australie] ; Mark Hertzberg [Australie] ; Karen Stapleton [Australie]Source :
- Australasian Journal of Dermatology [ 0004-8380 ] ; 2002-08.
English descriptors
- Teeft :
- Acitretin, Alcl, Anaplastic, Arthritis rheum, Cell lymphoma, Chemotherapy, Combination therapy, Conventional chemotherapy, Cutaneous, Dermatol, Enhancement, Initial presentation, Interferon, Isotretinoin, Lesion, Lung involvement, Lymphoma, Lymphoproliferative disorders, Methotrexate, Node, Nodule, Oral acitretin, Peripheral lymphoma, Primary cutaneous, Refractory, Refractory cases, Response rate, Response rates, Retinoic, Retinoic acid, Retinoids, Rheumatoid, Rheumatoid arthritis, Signal enhancement, Skin involvement, Spontaneous remission, Standard chemotherapy, Tumour, Ulcerated nodule, Units subcutaneously.
Abstract
Retinoids and interferon (IFN)‐α induce differentiation, affect cell proliferation and alter various immune parameters. In combination, their effects may be additive or even synergistic in the treatment of malignancy. We present a 53‐year‐old woman with stage IV CD30+ anaplastic large cell lymphoma with brain, lung and skin involvement. The patient had been on methotrexate for rheumatoid arthritis. After a combination of oral acitretin 50 mg daily and IFN‐α 3 million units subcutaneously 3 times per week, the skin lesions cleared within 2 months, lung lesions by 5 months and brain leisons by 7 months. Although we cannot exclude that methotrexate played a role in the development of this lymphoma and that its withdrawal contributed to the clearance of lesions, we propose that the patient's disease responded to the combination of acitretin and IFN‐α.
Url:
DOI: 10.1046/j.1440-0960.2002.00597.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002635
- to stream Istex, to step Curation: 002635
- to stream Istex, to step Checkpoint: 001009
- to stream Main, to step Merge: 002204
- to stream Main, to step Curation: 002182
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Stage IV CD30+ anaplastic large cell lymphoma: Response to acitretin and interferon‐α</title><author><name sortKey="Ong, Colin" sort="Ong, Colin" uniqKey="Ong C" first="Colin" last="Ong">Colin Ong</name></author><author><name sortKey="Sullivan, John" sort="Sullivan, John" uniqKey="Sullivan J" first="John" last="Sullivan">John Sullivan</name></author><author><name sortKey="Hertzberg, Mark" sort="Hertzberg, Mark" uniqKey="Hertzberg M" first="Mark" last="Hertzberg">Mark Hertzberg</name></author><author><name sortKey="Stapleton, Karen" sort="Stapleton, Karen" uniqKey="Stapleton K" first="Karen" last="Stapleton">Karen Stapleton</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8A4F7CFDF3CE5A19DCD2AECFEB91BD2D78E4E957</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1046/j.1440-0960.2002.00597.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-R2RJ6GQK-4/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002635</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002635</idno><idno type="wicri:Area/Istex/Curation">002635</idno><idno type="wicri:Area/Istex/Checkpoint">001009</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001009</idno><idno type="wicri:doubleKey">0004-8380:2002:Ong C:stage:iv:cd</idno><idno type="wicri:Area/Main/Merge">002204</idno><idno type="wicri:Area/Main/Curation">002182</idno><idno type="wicri:Area/Main/Exploration">002182</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Stage IV CD30+ anaplastic large cell lymphoma: Response to acitretin and interferon‐α</title><author><name sortKey="Ong, Colin" sort="Ong, Colin" uniqKey="Ong C" first="Colin" last="Ong">Colin Ong</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>1 Department of Dermatology, Westmead Hospital, Westmead, New South Wales, Australia 2 Department of Haematology, Westmead Hospital, Westmead, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Sullivan, John" sort="Sullivan, John" uniqKey="Sullivan J" first="John" last="Sullivan">John Sullivan</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>1 Department of Dermatology, Westmead Hospital, Westmead, New South Wales, Australia 2 Department of Haematology, Westmead Hospital, Westmead, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Hertzberg, Mark" sort="Hertzberg, Mark" uniqKey="Hertzberg M" first="Mark" last="Hertzberg">Mark Hertzberg</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>1 Department of Dermatology, Westmead Hospital, Westmead, New South Wales, Australia 2 Department of Haematology, Westmead Hospital, Westmead, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Stapleton, Karen" sort="Stapleton, Karen" uniqKey="Stapleton K" first="Karen" last="Stapleton">Karen Stapleton</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>1 Department of Dermatology, Westmead Hospital, Westmead, New South Wales, Australia 2 Department of Haematology, Westmead Hospital, Westmead, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Australasian Journal of Dermatology</title><title level="j" type="alt">AUSTRALASIAN JOURNAL DERMATOLOGY</title><idno type="ISSN">0004-8380</idno><idno type="eISSN">1440-0960</idno><imprint><biblScope unit="vol">43</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="207">207</biblScope><biblScope unit="page" to="210">210</biblScope><biblScope unit="page-count">4</biblScope><publisher>Blackwell Science Pty</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2002-08">2002-08</date></imprint><idno type="ISSN">0004-8380</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0004-8380</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acitretin</term><term>Alcl</term><term>Anaplastic</term><term>Arthritis rheum</term><term>Cell lymphoma</term><term>Chemotherapy</term><term>Combination therapy</term><term>Conventional chemotherapy</term><term>Cutaneous</term><term>Dermatol</term><term>Enhancement</term><term>Initial presentation</term><term>Interferon</term><term>Isotretinoin</term><term>Lesion</term><term>Lung involvement</term><term>Lymphoma</term><term>Lymphoproliferative disorders</term><term>Methotrexate</term><term>Node</term><term>Nodule</term><term>Oral acitretin</term><term>Peripheral lymphoma</term><term>Primary cutaneous</term><term>Refractory</term><term>Refractory cases</term><term>Response rate</term><term>Response rates</term><term>Retinoic</term><term>Retinoic acid</term><term>Retinoids</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Signal enhancement</term><term>Skin involvement</term><term>Spontaneous remission</term><term>Standard chemotherapy</term><term>Tumour</term><term>Ulcerated nodule</term><term>Units subcutaneously</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Retinoids and interferon (IFN)‐α induce differentiation, affect cell proliferation and alter various immune parameters. In combination, their effects may be additive or even synergistic in the treatment of malignancy. We present a 53‐year‐old woman with stage IV CD30+ anaplastic large cell lymphoma with brain, lung and skin involvement. The patient had been on methotrexate for rheumatoid arthritis. After a combination of oral acitretin 50 mg daily and IFN‐α 3 million units subcutaneously 3 times per week, the skin lesions cleared within 2 months, lung lesions by 5 months and brain leisons by 7 months. Although we cannot exclude that methotrexate played a role in the development of this lymphoma and that its withdrawal contributed to the clearance of lesions, we propose that the patient's disease responded to the combination of acitretin and IFN‐α.</div></front></TEI><affiliations><list><country><li>Australie</li></country></list><tree><country name="Australie"><noRegion><name sortKey="Ong, Colin" sort="Ong, Colin" uniqKey="Ong C" first="Colin" last="Ong">Colin Ong</name></noRegion><name sortKey="Hertzberg, Mark" sort="Hertzberg, Mark" uniqKey="Hertzberg M" first="Mark" last="Hertzberg">Mark Hertzberg</name><name sortKey="Stapleton, Karen" sort="Stapleton, Karen" uniqKey="Stapleton K" first="Karen" last="Stapleton">Karen Stapleton</name><name sortKey="Sullivan, John" sort="Sullivan, John" uniqKey="Sullivan J" first="John" last="Sullivan">John Sullivan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002182 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002182 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:8A4F7CFDF3CE5A19DCD2AECFEB91BD2D78E4E957
|texte= Stage IV CD30+ anaplastic large cell lymphoma: Response to acitretin and interferon‐α
}}
| This area was generated with Dilib version V0.6.33. |  |